CN1631902A - A kind of angelica polysaccharide and its preparation method and application - Google Patents
A kind of angelica polysaccharide and its preparation method and application Download PDFInfo
- Publication number
- CN1631902A CN1631902A CN 200410061139 CN200410061139A CN1631902A CN 1631902 A CN1631902 A CN 1631902A CN 200410061139 CN200410061139 CN 200410061139 CN 200410061139 A CN200410061139 A CN 200410061139A CN 1631902 A CN1631902 A CN 1631902A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- angelica
- radix angelicae
- angelicae sinensis
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 76
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 76
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims description 13
- 235000001287 Guettarda speciosa Nutrition 0.000 title description 63
- 244000061520 Angelica archangelica Species 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 168
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 22
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 17
- 239000006228 supernatant Substances 0.000 claims abstract description 17
- 239000012153 distilled water Substances 0.000 claims abstract description 16
- 238000010521 absorption reaction Methods 0.000 claims abstract description 13
- 239000000047 product Substances 0.000 claims abstract description 10
- 241000382455 Angelica sinensis Species 0.000 claims description 37
- 239000000706 filtrate Substances 0.000 claims description 18
- 239000012141 concentrate Substances 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 15
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 11
- 230000000202 analgesic effect Effects 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 10
- 238000000825 ultraviolet detection Methods 0.000 claims description 8
- 238000002270 exclusion chromatography Methods 0.000 claims description 4
- 229960004756 ethanol Drugs 0.000 claims 6
- BAHUBXAYVOCLNA-UHFFFAOYSA-N Isoangelol Natural products O1C(=O)C=CC2=C1C=C(OC)C(C(OC(=O)C(C)=CC)C(O)C(C)(C)O)=C2 BAHUBXAYVOCLNA-UHFFFAOYSA-N 0.000 claims 3
- 229930183733 angelol Natural products 0.000 claims 3
- 238000005057 refrigeration Methods 0.000 claims 3
- 201000002282 venous insufficiency Diseases 0.000 claims 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims 2
- 230000003544 deproteinization Effects 0.000 claims 2
- 239000008141 laxative Substances 0.000 claims 1
- 230000002475 laxative effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000007788 liquid Substances 0.000 abstract description 7
- 238000005119 centrifugation Methods 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 abstract description 3
- 241000213006 Angelica dahurica Species 0.000 abstract 3
- 230000036592 analgesia Effects 0.000 abstract 2
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 238000000151 deposition Methods 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 238000004088 simulation Methods 0.000 abstract 1
- 241000125175 Angelica Species 0.000 description 62
- 239000002244 precipitate Substances 0.000 description 51
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 208000005171 Dysmenorrhea Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 208000000114 Pain Threshold Diseases 0.000 description 8
- 230000037040 pain threshold Effects 0.000 description 8
- 238000000862 absorption spectrum Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229960000452 diethylstilbestrol Drugs 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000002356 laser light scattering Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
- 101800000989 Oxytocin Proteins 0.000 description 4
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 4
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 4
- 229960001723 oxytocin Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010046823 Uterine spasm Diseases 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- XNOPRXBHLZRZKH-MQYCRUOZSA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1C(CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-MQYCRUOZSA-N 0.000 description 1
- 229940082408 oxytocin injection Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域technical field
本发明涉及一种当归多糖及其制备方法和用途。The invention relates to an angelica polysaccharide, a preparation method and application thereof.
背景技术Background technique
当归属补益药,为伞形科(umbuiferae)当归属多年生草本植物当归[AngelicaSinensis(Oliv)Diels]的干燥根。当归有补血和血,活血化瘀,调经止痛之功效,临床上常依症将当归与其它药物配伍使用,用于月经不调、痛经、血虚头痛、腰腹疼痛等症。Angelica belongs to tonic medicine, which is the dry root of Angelica sinensis (Oliv) Diels, a perennial herb belonging to the umbrella family (umbuiferae). Angelica has the effects of enriching blood and blood, promoting blood circulation and removing blood stasis, regulating menstruation and relieving pain. Clinically, angelica is often used in combination with other medicines for irregular menstruation, dysmenorrhea, blood deficiency headache, waist and abdomen pain and other diseases.
当归的化学组成包括挥发油和水溶性组分两大部分。早期研究曾指出当归油对各种动物离体子宫,不论受孕者或未孕者都有弛缓作用。它在一定程度上为当归用于痛经治疗做出了解释。The chemical composition of angelica includes two major parts of volatile oil and water-soluble components. Early studies have pointed out that angelica oil has a relaxing effect on isolated uteri of various animals, both pregnant and non-pregnant. It partly explains the use of Angelica sinensis in the treatment of dysmenorrhea.
当归多糖存在于当归水溶性部位,它是由分子量不同的高分子化合物组成的同系混合物。近年来,当归多糖已被证明具有复杂的生物活性,能够调节机体的免疫功能,对抗皮质激素所引起的抑制,防止外周白细胞的减少和辐射损伤中的照射后效应,增强机体造血功能和抗肿瘤作用。Angelica polysaccharide exists in the water-soluble part of Angelica sinensis, which is a homologous mixture composed of polymer compounds with different molecular weights. In recent years, Angelica polysaccharides have been proved to have complex biological activities, which can regulate the body's immune function, resist the inhibition caused by corticosteroids, prevent the reduction of peripheral leukocytes and the post-irradiation effect in radiation damage, enhance the body's hematopoietic function and anti-tumor effect.
疼痛是常见的临床症状,寻找安全有效的非成瘾性镇痛药物一直是药物工作者十分重视的问题。“痛经”更是妇科常见病,中医认为其发病机理主要是气血受阻,血行不畅所致。当归作为中医的妇科要药,如何寻找到其有效治疗成分以进行中药现代化改革,使其符合现代剂型要求,是药物学界的研究热点。Pain is a common clinical symptom, and finding safe and effective non-addictive analgesics has always been a problem that drug workers attach great importance to. "Dysmenorrhea" is a common disease in gynecology. Traditional Chinese medicine believes that its pathogenesis is mainly due to obstruction of Qi and blood and poor blood circulation. Angelica is an important gynecological medicine in traditional Chinese medicine. How to find its effective therapeutic ingredients to modernize traditional Chinese medicine and make it meet the requirements of modern dosage forms is a research hotspot in the field of pharmacy.
《中国药学杂志》2002;37(10):746-8“当归粗多糖镇痛作用的实验研究”揭示当归粗多糖具有镇痛作用,但所用当归粗多糖中糖含量相对较低,还含有其它成分,且镇痛效果不明显。"Chinese Journal of Pharmaceutical Sciences" 2002; 37(10): 746-8 "Experimental Study on the Analgesic Effect of Angelica Crude Polysaccharides" revealed that Angelica sinensis crude polysaccharides have analgesic effects, but the sugar content in the Angelica sinensis crude polysaccharides used is relatively low and contains other ingredients, and the analgesic effect is not obvious.
发明内容Contents of the invention
本发明所要解决的问题是提供一种当归多糖制备方法和用途,所得当归多糖具有明显镇痛作用,尤其是治疗“痛经”有明显的效果。The problem to be solved by the present invention is to provide a preparation method and application of angelica polysaccharide, the obtained angelica polysaccharide has obvious analgesic effect, especially for treating "dysmenorrhea".
本发明提供的技术方案是:一种当归多糖,由下法制得:将当归醇沉物溶于蒸馏水,用Sevag法去蛋白直至紫外检测无280nm的蛋白质吸收峰,离心除去沉淀;保留水相,加入无水乙醇,沉淀多糖,弃上清液,所得沉淀物以无水乙醇洗涤,经冷冻干燥后,凝胶分子排阻层析分离,收集相对分子质量范围在1,0000-11,0000之间的分离产物,再经冷冻干燥后得到当归多糖。The technical scheme provided by the invention is: a kind of angelica polysaccharide, which is prepared by the following method: dissolve the alcohol precipitate of angelica sinensis in distilled water, use the Sevag method to remove protein until there is no protein absorption peak at 280nm in ultraviolet detection, and remove the precipitate by centrifugation; keep the water phase, Add absolute ethanol to precipitate the polysaccharide, discard the supernatant, wash the obtained precipitate with absolute ethanol, freeze-dry, and separate by gel molecular exclusion chromatography. The relative molecular mass range of the collection is 1,0000-11,0000 The isolated product between them was freeze-dried to obtain Angelica polysaccharide.
本发明还提供了上述当归多糖的制备方法,将当归醇沉物溶于蒸馏水,用Sevag法去蛋白直至紫外检测无280nm的蛋白质吸收峰,离心除去沉淀;保留水相,加入无水乙醇,沉淀多糖,弃上清液,所得沉淀物以无水乙醇洗涤至洗涤液呈无色,弃去洗涤液,洗涤后的沉淀物经冷冻干燥,凝胶分子排阻层析分离,收集相对分子质量范围在1,0000-11,0000之间的分离产物,再经冷冻干燥后得到当归多糖。The present invention also provides a preparation method of the above-mentioned angelica polysaccharide, which comprises dissolving the alcohol precipitate of angelica sinensis in distilled water, removing the protein by Sevag method until there is no protein absorption peak at 280nm in ultraviolet detection, and centrifuging to remove the precipitate; retaining the water phase, adding absolute ethanol, and precipitating Polysaccharide, discard the supernatant, wash the obtained precipitate with absolute ethanol until the washing liquid is colorless, discard the washing liquid, freeze-dry the washed precipitate, separate by gel size exclusion chromatography, and collect the relative molecular mass range The isolated product between 1,0000-110,000 is freeze-dried to obtain Angelica polysaccharide.
本发明中的上述原料当归醇沉物可来自中药制备过程中中药材常用提取方法所得当归醇沉物:即当归经水煮得到水提取物,水提取物经乙醇提取后的沉淀物。The alcohol precipitate of Angelica sinensis raw material in the present invention can come from the alcohol precipitate of Angelica sinensis obtained by the common extraction method of Chinese medicinal materials in the preparation process of traditional Chinese medicine: that is, the water extract of Angelica sinensis is boiled in water, and the precipitate of the water extract is extracted with ethanol.
本发明所得到的上述当归多糖属于聚合物,其分子量代表的是相似链长的平均配布。经鉴定本发明的当归多糖的物化性质为:相对分子质量范围在1,0000-11,0000之间(采用凝胶渗透色谱-激光光散射联用技术),易溶于水,糖含量大于95%,经HPLC检测表明主要由葡萄糖、阿拉伯糖、半乳糖、鼠李糖和木糖组成,并且紫外吸收光谱显示192nm处有明显吸收峰;红外吸收光谱分析,在3352cm-1、2940cm-1、1747cm-1、1626cm-1、1414cm-1、1237cm-1、1021cm-1及536cm-1处表现为典型的多糖吸收峰。The above-mentioned angelica polysaccharide obtained in the present invention belongs to a polymer, and its molecular weight represents the average distribution of similar chain lengths. The physical and chemical properties of the angelica polysaccharide identified in the present invention are as follows: the relative molecular mass range is between 1,0000-11,0000 (using gel permeation chromatography-laser light scattering combined technology), easily soluble in water, and the sugar content is greater than 95 %, HPLC detection shows that it is mainly composed of glucose, arabinose, galactose, rhamnose and xylose, and the ultraviolet absorption spectrum shows an obvious absorption peak at 192nm; infrared absorption spectrum analysis, at 3352cm -1 , 2940cm -1 , Typical polysaccharide absorption peaks were observed at 1747cm -1 , 1626cm -1 , 1414cm -1 , 1237cm -1 , 1021cm -1 and 536cm -1 .
本发明的上述当归多糖在制备镇痛药物尤其是治疗痛经药物中的用途。如将本发明的当归多糖用于制备胶囊、片剂、颗粒剂以及注射剂,所得药物具有明显的镇痛作用,尤其是治疗“痛经”效果显著。Use of the above-mentioned angelica polysaccharide of the present invention in the preparation of analgesic drugs, especially drugs for treating dysmenorrhea. If the angelica polysaccharide of the present invention is used to prepare capsules, tablets, granules and injections, the obtained medicine has obvious analgesic effect, especially the effect of treating "dysmenorrhea" is remarkable.
按背景技术中的当归粗多糖(糖含量为65.5%)一次性口服给药0.25g/kg时,对化学物质和热刺激引起疼痛的模型有明显镇痛作用,而本发明的当归多糖在一次性口服给药0.025g/kg时即可产生相当作用,使用剂量下降90%,并且随剂量增加镇痛作用增强。When the Angelica sinensis crude polysaccharide (sugar content is 65.5%) in the background technology is once-administered 0.25g/kg, it has obvious analgesic effect to the model that chemical substance and heat stimulation cause pain, and the Angelica sinensis polysaccharide of the present invention once A comparable effect can be produced when oral administration of 0.025g/kg is administered, the dosage is reduced by 90%, and the analgesic effect is enhanced with the increase of dosage.
具体实施方式Detailed ways
以下结合具体的实例对本发明的技术方案作进一步说明:The technical scheme of the present invention will be further described below in conjunction with specific examples:
本发明中的上述原料当归醇沉物可来自中药制备过程中中药材常用提取方法所得当归醇沉物:即当归经水煮得到水提取物,水提取物经乙醇提取后的沉淀物。The alcohol precipitate of Angelica sinensis raw material in the present invention can come from the alcohol precipitate of Angelica sinensis obtained by the common extraction method of Chinese medicinal materials in the preparation process of traditional Chinese medicine: that is, the water extract of Angelica sinensis is boiled in water, and the precipitate of the water extract is extracted with ethanol.
当归醇沉物也可由下法得到:所述当归醇沉物按下法制得,取当归饮片,加入5~7倍当归饮片重量的水煎煮30~60分钟,滤过;将所得药渣加入3~6倍重量(药渣)的水进行煎煮30~50分钟,滤过;所得药渣加入3~6倍重量(药渣)的水煎煮30~50分钟,滤过;合并三次滤液,并将滤液浓缩;合并三次滤液,浓缩,冷却至室温,加入乙醇至乙醇含量为40%~60%(体积比,下同),2~4℃冷藏24~48小时,滤过,得沉淀物;再次浓缩,加入乙醇至乙醇含量为70%~80%,2~4℃冷藏24~48小时,滤过,得沉淀物;第三次浓缩,加入乙醇至乙醇含量为80%~90%,2~4℃冷藏24~48小时,滤过,得沉淀物;合并三次沉淀物得当归醇沉物。Angelica alcohol precipitation can also be obtained by the following method: the angelica alcohol precipitation is prepared according to the following method, take angelica decoction pieces, add water 5 to 7 times the weight of angelica decoction pieces, decoct for 30 to 60 minutes, filter; Decoct 3-6 times the weight (dregs) of water for 30-50 minutes, filter; add 3-6 times the weight (dregs) of water to decoct for 30-50 minutes, filter; combine the three filtrates , and concentrate the filtrate; combine the three filtrates, concentrate, cool to room temperature, add ethanol until the ethanol content is 40% to 60% (volume ratio, the same below), refrigerate at 2 to 4°C for 24 to 48 hours, filter to obtain a precipitate Concentrate again, add ethanol until the ethanol content is 70%-80%, refrigerate at 2-4°C for 24-48 hours, filter to obtain a precipitate; concentrate for the third time, add ethanol until the ethanol content is 80%-90% , refrigerated at 2 to 4°C for 24 to 48 hours, filtered to obtain a precipitate; the three precipitates were combined to obtain an angelica alcohol precipitate.
本发明当归多糖的制备:将当归醇沉物溶于蒸馏水,加入乙醇至乙醇含量为70%~80%抽提,2~4℃冷藏24~48小时,弃上清,保留沉淀,重复进行此步骤直至上清液无色,保留沉淀。再次将沉淀重新溶于蒸馏水,用Sevag法去蛋白直至紫外检测无280nm的蛋白质吸收峰,离心除去变性蛋白。保留水相,加入3~4倍体积的无水乙醇,于2~4℃冷藏24~48小时,弃上清。沉淀部分以无水乙醇洗涤至洗涤液呈无色,弃去洗涤液,待乙醇自然挥发后,冷冻干燥5~20小时,所得产物属于聚合物,其分子量代表的是相似链长的平均配布。经凝胶分子排阻层析分离,收集相对分子质量范围在1,0000-11,0000之间的分离产物,再经冷冻干燥后得到当归多糖。经鉴定本发明所得当归多糖的物化性质为:相对分子质量范围在1,0000-11,0000之间(采用凝胶渗透色谱-激光光散射联用技术),易溶于水,糖含量大于95%,经HPLC检测表明主要由葡萄糖、阿拉伯糖、半乳糖、鼠李糖和木糖组成,并且紫外吸收光谱显示192nm处有明显吸收峰;红外吸收光谱分析,在3352cm-1、2940cm-1、1747cm-1、1626cm-1、1414cm-1、1237cm-1、1021cm-1及536cm-1处表现为典型的多糖吸收峰。The preparation of angelica polysaccharides of the present invention: dissolve the alcohol precipitate of angelica sinensis in distilled water, add ethanol until the ethanol content is 70% to 80% for extraction, refrigerate at 2 to 4°C for 24 to 48 hours, discard the supernatant, keep the precipitate, and repeat the process Step until the supernatant is colorless, save the pellet. The precipitate was redissolved in distilled water again, protein was removed by Sevag method until there was no protein absorption peak at 280nm in ultraviolet detection, and denatured protein was removed by centrifugation. Keep the water phase, add 3 to 4 times the volume of absolute ethanol, refrigerate at 2 to 4°C for 24 to 48 hours, and discard the supernatant. The precipitated part is washed with absolute ethanol until the washing liquid is colorless, discarding the washing liquid, and after the ethanol volatilizes naturally, freeze-dry for 5-20 hours. The obtained product belongs to a polymer, and its molecular weight represents the average distribution of similar chain lengths. Separation by gel molecular exclusion chromatography, collecting isolated products with a relative molecular mass ranging from 1,0000 to 11,0000, and then freeze-drying to obtain Angelica polysaccharide. The physical and chemical properties of Angelica polysaccharide obtained in the present invention are identified as follows: the relative molecular mass range is between 1,0000-11,0000 (using gel permeation chromatography-laser light scattering combined technology), easily soluble in water, and the sugar content is greater than 95 %, HPLC detection shows that it is mainly composed of glucose, arabinose, galactose, rhamnose and xylose, and the ultraviolet absorption spectrum shows an obvious absorption peak at 192nm; infrared absorption spectrum analysis, at 3352cm -1 , 2940cm -1 , Typical polysaccharide absorption peaks were observed at 1747cm -1 , 1626cm -1 , 1414cm -1 , 1237cm -1 , 1021cm -1 and 536cm -1 .
实施例1:取当归饮片加入5倍(重量比)水煎煮30分钟,滤过;将所得药渣加入3倍(重量比)水进行煎煮30分钟,滤过;所得药渣加入3倍(重量比)水煎煮30分钟,滤过;合并三次滤液,并将滤液浓缩。合并三次滤液,浓缩,冷却至室温,加入乙醇至乙醇含量为40%(v/v),4℃冷藏24小时,滤过,保留沉淀即当归醇沉物;再次浓缩,加入乙醇至乙醇含量为70%(v/v),4℃冷藏24小时,滤过,保留沉淀即当归醇沉物;第三次浓缩,加入乙醇至乙醇含量为80%(v/v),4℃冷藏24小时,滤过,保留沉淀即当归醇沉物。合并沉淀即合并当归醇沉物,将其重新溶于蒸馏水,加入乙醇至乙醇含量为70%(v/v)抽提,4℃冷藏24小时,弃上清,保留沉淀,重复进行此步骤直至上清液无色,保留沉淀。再次将沉淀重新溶于蒸馏水,用Sevag法去蛋白直至紫外检测无280nm的蛋白质吸收峰,离心除去变性蛋白。保留水相,加入4倍体积的无水乙醇,于4℃冷藏24小时,弃上清。沉淀部分以无水乙醇洗涤至洗涤液呈无色,弃去洗涤液,待乙醇自然挥发后,冷冻干燥5小时;以TSK-Gel4000H型柱(细孔孔径600埃),柱尺寸250×10mm,以蒸馏水为流动相,流量10ml/min,收集5-60min的分离产物;再经冷冻干燥后得到当归多糖。采用凝胶渗透色谱-激光光散射联用技术,HPLC以及红外吸收光谱分析鉴定上述当归多糖的得率为10%,纯度为96%。Embodiment 1: Take Angelica decoction pieces and add 5 times (by weight) water to decoct for 30 minutes, filter; add 3 times (weight ratio) water to the obtained medicinal residues and decoct for 30 minutes, filter; add 3 times the obtained medicinal residues (weight ratio) decoct in water for 30 minutes, filter; combine the three filtrates, and concentrate the filtrate. Combine the three filtrates, concentrate, cool to room temperature, add ethanol until the ethanol content is 40% (v/v), refrigerate at 4°C for 24 hours, filter, keep the precipitate that is the alcohol precipitate of Angelica sinensis; concentrate again, add ethanol until the ethanol content is 70% (v/v), refrigerated at 4°C for 24 hours, filtered, and retained the precipitate, namely the alcohol precipitate of Angelica sinensis; the third concentration, adding ethanol until the ethanol content was 80% (v/v), refrigerated at 4°C for 24 hours, Filtrate, and keep the precipitate, that is, the angelica alcohol precipitate. Merge the precipitation, that is, combine the alcohol precipitate of Angelica sinensis, redissolve it in distilled water, add ethanol until the ethanol content is 70% (v/v) for extraction, refrigerate at 4°C for 24 hours, discard the supernatant, keep the precipitate, and repeat this step until The supernatant was colorless and the precipitate remained. The precipitate was redissolved in distilled water again, the protein was removed by Sevag method until there was no protein absorption peak at 280nm by UV detection, and the denatured protein was removed by centrifugation. Keep the aqueous phase, add 4 times the volume of absolute ethanol, refrigerate at 4°C for 24 hours, and discard the supernatant. The precipitated part was washed with absolute ethanol until the washing solution was colorless, discarded the washing solution, and after the ethanol volatilized naturally, freeze-dried for 5 hours; with a TSK-Gel4000H column (pore diameter of 600 angstroms), the column size was 250 × 10mm, Using distilled water as the mobile phase with a flow rate of 10ml/min, collecting the isolated product for 5-60min; and then freeze-drying to obtain Angelica polysaccharide. The gel permeation chromatography-laser light scattering combined technique, HPLC and infrared absorption spectrum analysis were used to identify the yield of the polysaccharide of Angelica sinensis 10%, and the purity was 96%.
实施例2:取当归饮片加入7倍(重量比)水煎煮60分钟,滤过;将所得药渣加入5倍(重量比)水进行煎煮40分钟,滤过;所得药渣加入3倍(重量比)水煎煮40分钟,滤过;合并三次滤液,并将滤液浓缩。合并三次滤液,浓缩,冷却至室温,加入乙醇至乙醇含量为60%(v/v),2℃冷藏48小时,滤过,保留沉淀即当归醇沉物;再次浓缩,加入乙醇至乙醇含量为80%(v/v),2℃冷藏48小时,滤过,保留沉淀即当归醇沉物;第三次浓缩,加入乙醇至乙醇含量为80%(v/v),2℃冷藏48小时,滤过,保留沉淀即当归醇沉物。合并沉淀即合并当归醇沉物,将其重新溶于蒸馏水,加入乙醇至乙醇含量为80%(v/v)抽提,2℃冷藏48小时,弃上清,保留沉淀,重复进行此步骤直至上清液无色,保留沉淀。再次将沉淀重新溶于蒸馏水,用Sevag法去蛋白直至紫外检测无280nm的蛋白质吸收峰,离心除去变性蛋白。保留水相,加入3倍体积的无水乙醇,于2℃冷藏48小时,弃上清。沉淀部分以无水乙醇洗涤至洗涤液呈无色,弃去洗涤液,待乙醇自然挥发后,冷冻干燥10小时;以TSK-Gel4000H型柱(细孔孔径600埃),柱尺寸250×10mm,以蒸馏水为流动相,流量10ml/min,收集5-60min的分离产物;再经冷冻干燥后得到当归多糖。采用凝胶渗透色谱-激光光散射联用技术,HPLC以及红外吸收光谱分析鉴定上述当归多糖的得率为30%,纯度为97%。Embodiment 2: Take Angelica decoction pieces and add 7 times (weight ratio) water to decoct for 60 minutes, filter; add 5 times (weight ratio) water to the obtained medicinal residues and decoct for 40 minutes, filter; obtained medicinal residues add 3 times (weight ratio) decoct in water for 40 minutes, filter; combine the three filtrates, and concentrate the filtrate. Combine the three filtrates, concentrate, cool to room temperature, add ethanol until the ethanol content is 60% (v/v), refrigerate at 2°C for 48 hours, filter, keep the precipitate that is the alcohol precipitate of Angelica sinensis; concentrate again, add ethanol until the ethanol content is 80% (v/v), refrigerated at 2°C for 48 hours, filtered, and retained the precipitate that is the alcohol precipitate of Angelica sinensis; the third concentration, adding ethanol until the ethanol content was 80% (v/v), refrigerated at 2°C for 48 hours, Filtrate, and keep the precipitate, that is, the angelica alcohol precipitate. Merge the precipitation, that is, combine the alcohol precipitate of Angelica sinensis, redissolve it in distilled water, add ethanol until the ethanol content is 80% (v/v) for extraction, refrigerate at 2°C for 48 hours, discard the supernatant, keep the precipitate, and repeat this step until The supernatant was colorless and the precipitate remained. The precipitate was redissolved in distilled water again, protein was removed by Sevag method until there was no protein absorption peak at 280nm in ultraviolet detection, and denatured protein was removed by centrifugation. Keep the aqueous phase, add 3 times the volume of absolute ethanol, refrigerate at 2°C for 48 hours, and discard the supernatant. The precipitated part was washed with absolute ethanol until the washing liquid was colorless, and the washing liquid was discarded. After the ethanol volatilized naturally, it was freeze-dried for 10 hours; with a TSK-Gel4000H column (pore diameter 600 angstroms), the column size was 250 × 10mm, Using distilled water as the mobile phase, the flow rate is 10ml/min, and the isolated product is collected for 5-60min; then freeze-dried to obtain the polysaccharide of Angelica sinensis. The gel permeation chromatography-laser light scattering combined technique, HPLC and infrared absorption spectrum analysis were used to identify the yield of the polysaccharide from Angelica sinensis to 30%, and the purity was 97%.
实施例3:取当归饮片加入6倍(重量比)水煎煮50分钟,滤过;将所得药渣加入6倍(重量比)水进行煎煮50分钟,滤过;所得药渣加入6倍(重量比)水煎煮50分钟,滤过;合并三次滤液,并将滤液浓缩。合并三次滤液,浓缩,冷却至室温,加入乙醇至乙醇含量为50%(v/v),4℃冷藏48小时,滤过,保留沉淀即当归醇沉物;再次浓缩,加入乙醇至乙醇含量为80%(v/v),4℃冷藏48小时,滤过,保留沉淀即当归醇沉物;第三次浓缩,加入乙醇至乙醇含量为90%(v/v),4℃冷藏48小时,滤过,保留沉淀即当归醇沉物。合并沉淀即合并当归醇沉物,将其重新溶于蒸馏水,加入乙醇至乙醇含量为70%(v/v)抽提,4℃冷藏48小时,弃上清,保留沉淀,重复进行此步骤直至上清液无色,保留沉淀。再次将沉淀重新溶于蒸馏水,用Sevag法去蛋白直至紫外检测无280nm的蛋白质吸收峰,离心除去变性蛋白。保留水相,加入4倍体积的无水乙醇,于4℃冷藏24小时,弃上清。沉淀部分以无水乙醇洗涤至洗涤液呈无色,弃去洗涤液,待乙醇自然挥发后,冷冻干燥20小时;以TSK-Gel4000H型柱(细孔孔径600埃),柱尺寸250×10mm,以蒸馏水为流动相,流量10ml/min,收集5-60min的分离产物;再经冷冻干燥后得到当归多糖。采用凝胶渗透色谱-激光光散射联用技术,HPLC以及红外吸收光谱分析鉴定上述当归多糖的得率为40%,纯度为96%。Embodiment 3: Get Angelica decoction pieces and add 6 times (weight ratio) water to decoct for 50 minutes, filter; Add 6 times (weight ratio) water to the obtained medicinal residues and decoct for 50 minutes, filter; Gained medicinal residues add 6 times (weight ratio) decoct in water for 50 minutes, filter; combine three filtrates, and concentrate the filtrate. Combine the three filtrates, concentrate, cool to room temperature, add ethanol until the ethanol content is 50% (v/v), refrigerate at 4°C for 48 hours, filter, keep the precipitate, which is the alcohol precipitate of Angelica sinensis; concentrate again, add ethanol until the ethanol content is 80% (v/v), refrigerated at 4°C for 48 hours, filtered, and retained the precipitate that is the alcohol precipitate of Angelica sinensis; the third concentration, adding ethanol until the ethanol content was 90% (v/v), refrigerated at 4°C for 48 hours, Filtrate, and keep the precipitate, that is, the angelica alcohol precipitate. Merge the precipitation, that is, combine the alcohol precipitate of Angelica sinensis, redissolve it in distilled water, add ethanol until the ethanol content is 70% (v/v) for extraction, refrigerate at 4°C for 48 hours, discard the supernatant, keep the precipitate, and repeat this step until The supernatant was colorless and the precipitate remained. The precipitate was redissolved in distilled water again, protein was removed by Sevag method until there was no protein absorption peak at 280nm in ultraviolet detection, and denatured protein was removed by centrifugation. Keep the aqueous phase, add 4 times the volume of absolute ethanol, refrigerate at 4°C for 24 hours, and discard the supernatant. The precipitated part was washed with absolute ethanol until the washing solution was colorless, and the washing solution was discarded. After the ethanol volatilized naturally, it was freeze-dried for 20 hours; with a TSK-Gel4000H column (pore diameter 600 angstroms), the column size was 250 × 10mm, Using distilled water as the mobile phase, the flow rate is 10ml/min, and the isolated product is collected for 5-60min; then freeze-dried to obtain the polysaccharide of Angelica sinensis. The gel permeation chromatography-laser light scattering combined technique, HPLC and infrared absorption spectrum analysis were used to identify the yield of the polysaccharide from Angelica sinensis to 40%, and the purity was 96%.
实施例4:用本发明当归多糖制备镇痛的药物:当归多糖加入赋形剂,按常规方法制成片剂。Example 4: Preparation of analgesic drug using Angelica polysaccharide of the present invention: Angelica polysaccharide is added with excipients, and made into tablets according to conventional methods.
实施例5:用本发明当归多糖制备镇痛的药物:当归多糖加入赋形剂,按常规方法制成胶囊。Example 5: Preparation of analgesic drug using Angelica polysaccharide of the present invention: Angelica polysaccharide is added with excipients and made into capsules according to conventional methods.
实施例6:用本发明当归多糖制备镇痛的药物:当归多糖溶解于注射用水中,按常规方法制成针剂。Example 6: Preparation of analgesic drug using Angelica polysaccharide of the present invention: Angelica polysaccharide was dissolved in water for injection, and injection was prepared according to conventional methods.
动物试验:Animal testing:
1.药物:己烯雌酚注射液,上海第九制药厂,批号:020906。缩宫素注射液,南京生物化学制药厂,批号:030409。1. Drug: diethylstilbestrol injection, Shanghai Ninth Pharmaceutical Factory, batch number: 020906. Oxytocin injection, Nanjing Biochemical Pharmaceutical Factory, batch number: 030409.
(2)主要仪器GL-8402型热板测痛仪,浙江宁海医药仪器厂生产。(2) The main instrument GL-8402 hot plate pain measuring instrument, produced by Zhejiang Ninghai Medical Instrument Factory.
(3)动物健康昆明种小鼠,除“痛经模型”选用♂小鼠作为阴性对照外,其它实验均用♀小鼠,体重18±1g,由武汉大学动物实验中心提供,合格证号:SCXK(鄂)2003-2004。(3) Animal health Kunming mice, except for the "dysmenorrhea model" which uses ♂ mice as negative controls, other experiments use ♀ mice, weighing 18±1g, provided by the Animal Experiment Center of Wuhan University, certificate number: SCXK (E) 2003-2004.
2.方法2. Method
(1)本发明当归多糖对醋酸所致雌性小鼠扭体反应的影响(1) Effect of Angelica polysaccharide of the present invention on writhing response of female mice caused by acetic acid
动物分组和药物剂量见表1,实验前1小时经口给药背景技术中的当归粗多糖(糖含量为65.5%)或本发明的当归多糖,模型组给予等容量生理盐水。给药后1小时腹腔注射1%醋酸0.2ml/只,观察给药小鼠扭体反应潜伏期及30min内扭体次数,并计算保护百分率。See Table 1 for animal grouping and drug dosage. Angelica sinensis crude polysaccharide (sugar content: 65.5%) in the background technology or Angelica sinensis polysaccharide of the present invention was orally administered 1 hour before the experiment, and the model group was given normal saline of equal volume. One hour after administration, 0.2ml of 1% acetic acid was injected intraperitoneally, and the latent period of writhing reaction and the number of times of writhing within 30 minutes were observed in the administered mice, and the protection percentage was calculated.
(2)本发明当归多糖对热板法镇痛作用的影响(2) The influence of Angelica polysaccharide of the present invention on the analgesic effect of hot plate method
预先以55℃热板对♀小鼠进行筛选,在10~30秒内出现舔足反应的为合格小鼠。实验分组和药物剂量见表2。实验前1小时经口灌胃(ig)给予受试药,模型组给予等容量生理盐水。为避免痛阈周期性波动的影响,实验均在上午8~10时进行,室温25±1℃。记录各组痛阈的变化,并计算痛阈提高百分率。若60秒内末出现舔足反应,痛阈计为60秒。The ♀ mice were screened on a 55°C hot plate in advance, and the mice that showed a foot-licking response within 10 to 30 seconds were qualified mice. The experimental groups and drug doses are shown in Table 2. One hour before the experiment, the test drug was given by oral gavage (ig), and the model group was given the same volume of normal saline. In order to avoid the influence of the periodic fluctuation of the pain threshold, the experiments were carried out at 8-10 a.m. at a room temperature of 25±1°C. The change of pain threshold in each group was recorded, and the percentage increase of pain threshold was calculated. If there is no foot licking reaction within 60 seconds, the pain threshold is counted as 60 seconds.
(3)本发明当归多糖对己烯雌酚和缩宫素诱发小鼠子宫痉挛的影响(3) Effect of Angelica polysaccharide of the present invention on diethylstilbestrol and oxytocin-induced mouse uterine spasms
各组动物于实验前皮下注射己烯雌酚0.2mg/只,连续3天。实验当日,动物经口灌胃(ig)给予当归粗多糖或本发明所述的一种当归多糖,模型组给予等容量生理盐水,1小时后ip缩宫素0.3u/只。观察各组动物扭体反应潜伏期及30min内扭体次数。若30min内不出现扭体反应,潜伏期计为30min。Animals in each group were subcutaneously injected with 0.2 mg of diethylstilbestrol per animal for 3 consecutive days before the experiment. On the day of the experiment, the animals were orally administered with Angelica sinensis crude polysaccharide or an Angelica sinensis polysaccharide described in the present invention, and the model group was given an equal volume of normal saline, and ip oxytocin 0.3u/animal after 1 hour. The latent period of writhing reaction and the number of writhing times within 30 min were observed in each group. If there is no writhing reaction within 30 minutes, the incubation period is counted as 30 minutes.
3.结果3. Results
(1)本发明当归多糖对疼痛模型——醋酸所致雌性小鼠扭体反应的影响实验,结果见表1。(1) The effect experiment of Angelica polysaccharide of the present invention on pain model—writhing response of female mice induced by acetic acid, the results are shown in Table 1.
表1 本发明当归多糖对醋酸所致扭体反应的影响.n(例数)=10,x±s(均数±标准差)Table 1 The influence of Angelica polysaccharide of the present invention on writhing reaction caused by acetic acid. n (number of cases)=10, x ± s (mean ± standard deviation)
扭体反应writhing reaction
分组 剂量(g·kg-1)Group Dose (g·kg -1 )
潜伏期(min) 次数(次/30min) 保护率(%)Incubation period (min) Times (times/30min) Protection rate (%)
模型组 / 5.2±1.8 34.2±8.8 /Model group / 5.2±1.8 34.2±8.8 /
当归粗多糖 0.075 6.9±1.51) 22.9±6.92) 33.0Angelica crude polysaccharide 0.075 6.9±1.5 1) 22.9±6.9 2) 33.0
0.250 19.3±6.82) 7.4±5.02) 78.40.250 19.3±6.8 2) 7.4±5.0 2) 78.4
一种当归多糖 0.025 14.1±7.82) 10.3±5.32) 69.9An angelica polysaccharide 0.025 14.1±7.8 2) 10.3±5.3 2) 69.9
0.075 23.1±6.92) 5.9±4.82) 82.70.075 23.1±6.9 2) 5.9±4.8 2) 82.7
注:与模型对照组比较,1)P<0.05,2)P<0.01.Note: Compared with the model control group, 1) P<0.05, 2) P<0.01.
结果表明,本发明的当归多糖在仅为当归粗多糖1/10剂量时即可明显产生对醋酸所致疼痛的保护作用,并且随剂量增加作用增强。The results show that the angelica polysaccharide of the present invention can obviously produce a protective effect on the pain caused by acetic acid at only 1/10 dose of the angelica crude polysaccharide, and the effect is enhanced with the increase of the dose.
(2)本发明当归多糖对热板法致痛作用的影响实验。结果见表2。(2) Experiment of the influence of the polysaccharide of Angelica sinensis of the present invention on the pain-inducing effect of the hot plate method. The results are shown in Table 2.
表2 本发明当归多糖对雌性小鼠热板法致痛的影响.n(例数)=10,x±s(均数±标准差)Table 2 The effect of Angelica polysaccharide of the present invention on the pain induced by hot plate method in female mice. n (number of cases)=10, x ± s (mean ± standard deviation)
给药前痛阈时Pain threshold before administration
剂量 给药后痛阈时 痛阈提高时 痛阈提高Dosage After administration Pain threshold Pain threshold increased Pain threshold increased
分组 间group room
(g·kg-1) 间(s) 间(s) 率(%)(g·kg -1 ) Room(s) Room(s) Rate(%)
(s)(s)
模型组 / 20.8±6.4 21.2±6.8 1.3±1.5 1.9Model group / 20.8±6.4 21.2±6.8 1.3±1.5 1.9
当归粗多糖 0.075 21.5±6.3 24.9±7.7 4.4±5.4 15.8Angelica crude polysaccharide 0.075 21.5±6.3 24.9±7.7 4.4±5.4 15.8
0.250 23.4±4.4 34.6±9.3 11.7±8.21) 47.90.250 23.4±4.4 34.6±9.3 11.7±8.2 1) 47.9
一种当归多糖 0.025 20.7±5.2 29.4±9.1 9.1±8.11) 42.0An angelica polysaccharide 0.025 20.7±5.2 29.4±9.1 9.1±8.1 1) 42.0
0.075 21.3±6.2 34.8±8.7 13.7±9.61) 63.40.075 21.3±6.2 34.8±8.7 13.7±9.6 1) 63.4
注:与对照组比较,1)P<0.01.Note: Compared with the control group, 1) P<0.01.
结果表明,本发明的当归多糖在仅为当归粗多糖1/10剂量时即可显著保护热刺激所致疼痛,并且随剂量增加作用增强。The results show that the angelica polysaccharide of the present invention can significantly protect the pain caused by heat stimulation at only 1/10 dose of the angelica crude polysaccharide, and the effect is enhanced with the increase of the dose.
(3)本发明当归多糖对“痛经模型”——己烯雌酚和缩宫素诱发小鼠子宫痉挛的影响实验,结果见表3。(3) The experiment of the effect of Angelica polysaccharide of the present invention on the "dysmenorrhea model" - diethylstilbestrol and oxytocin-induced uterine cramps in mice, the results are shown in Table 3.
表3 本发明当归多糖对己烯雌酚和缩宫素所致小鼠子宫痉挛的影响.Table 3 Effect of Angelica polysaccharide of the present invention on uterine spasm in mice induced by diethylstilbestrol and oxytocin.
n(例数)=10,x±s(均数±标准差)n (number of cases) = 10, x ± s (mean ± standard deviation)
扭体反应writhing reaction
分组 剂量(g·kg-1)Group Dose (g·kg -1 )
潜伏期(min) 次数(次/30min) 发生率(%)Incubation period (min) Times (times/30min) Occurrence rate (%)
模型组 / 12.3±3.8 6.3±4.0 100Model Group / / 12.3±3.8 6.3±4.0 100
当归粗多糖 0.075 21.1±9.01) 2.0±2.11) 60Angelica crude polysaccharide 0.075 21.1±9.0 1) 2.0±2.1 1) 60
0.250 23.2±8.82) 1.3±1.92) 401) 0.250 23.2±8.8 2) 1.3±1.9 2) 40 1)
一种当归多糖 0.025 25.4±6.62) 0.9±1.32) 401) An angelica polysaccharide 0.025 25.4±6.6 2) 0.9±1.3 2) 40 1)
0.075 27.7±4.92) 0.6±1.32) 302) 0.075 27.7±4.9 2) 0.6±1.3 2) 30 2)
注:与模型组比较,1)P<0.05,2)P<0.01.Note: Compared with the model group, 1) P<0.05, 2) P<0.01.
上述结果表明,本发明的当归多糖一次性口服给药0.025g/kg和0.075g/kg对化学物质和热刺激引起疼痛的模型有明显镇痛作用,并明显抑制“痛经”所致小鼠扭体反应即能有效对抗雌性激素诱发“痛经”所引起的疼痛反应。实验说明,本发明的当归多糖在当归粗多糖1/10剂量下即有明显作用,并且随剂量增加作用增强。The above results show that the one-time oral administration of 0.025g/kg and 0.075g/kg of Angelica polysaccharide of the present invention has obvious analgesic effect on the pain model caused by chemical substances and heat stimulation, and significantly inhibits the pain caused by "dysmenorrhea" in mice. The body response can effectively counteract the pain response caused by estrogen-induced "dysmenorrhea". Experiments show that the angelica polysaccharide of the present invention has a significant effect at 1/10 dose of the angelica crude polysaccharide, and the effect is enhanced with the increase of the dose.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410061139 CN1273493C (en) | 2004-11-18 | 2004-11-18 | Angelica polysaccharide and its preparation and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410061139 CN1273493C (en) | 2004-11-18 | 2004-11-18 | Angelica polysaccharide and its preparation and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1631902A true CN1631902A (en) | 2005-06-29 |
| CN1273493C CN1273493C (en) | 2006-09-06 |
Family
ID=34846295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410061139 Expired - Fee Related CN1273493C (en) | 2004-11-18 | 2004-11-18 | Angelica polysaccharide and its preparation and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1273493C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101235097B (en) * | 2008-02-29 | 2010-11-24 | 武汉大学 | A kind of method and application of extracting polysaccharide from angelica |
| CN101020719B (en) * | 2006-02-14 | 2011-01-12 | 北京美迪克斯生物技术有限公司 | Composite angelica polysaccharide and its preparation process and use |
| CN102154351A (en) * | 2010-12-30 | 2011-08-17 | 江苏大学 | Cationic angelica polysaccharide nanoparticle gene delivery system and preparation method thereof |
| CN106349401A (en) * | 2016-08-30 | 2017-01-25 | 甘肃中医药大学 | Method for optimizing parameters of radix angelica sinensis polysaccharide extracting technology based on response surface method |
| CN108771005A (en) * | 2018-06-19 | 2018-11-09 | 佛山推启农业研究院(普通合伙) | A kind of lactagogue forage and preparation method thereof |
| CN110283257A (en) * | 2019-06-28 | 2019-09-27 | 浙江理工大学 | A kind of extracting method of Radix Angelicae Sinensis polysaccharide |
| CN111297888A (en) * | 2020-04-01 | 2020-06-19 | 中国人民解放军第四军医大学 | Application of angelica polysaccharide in colitis |
| CN112870215A (en) * | 2018-09-26 | 2021-06-01 | 甘肃中医药大学 | Application of angelica polysaccharide |
-
2004
- 2004-11-18 CN CN 200410061139 patent/CN1273493C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101020719B (en) * | 2006-02-14 | 2011-01-12 | 北京美迪克斯生物技术有限公司 | Composite angelica polysaccharide and its preparation process and use |
| CN101235097B (en) * | 2008-02-29 | 2010-11-24 | 武汉大学 | A kind of method and application of extracting polysaccharide from angelica |
| CN102154351A (en) * | 2010-12-30 | 2011-08-17 | 江苏大学 | Cationic angelica polysaccharide nanoparticle gene delivery system and preparation method thereof |
| CN102154351B (en) * | 2010-12-30 | 2012-12-19 | 江苏大学 | Cationic angelica polysaccharide nanoparticle gene delivery system and preparation method thereof |
| CN106349401A (en) * | 2016-08-30 | 2017-01-25 | 甘肃中医药大学 | Method for optimizing parameters of radix angelica sinensis polysaccharide extracting technology based on response surface method |
| CN108771005A (en) * | 2018-06-19 | 2018-11-09 | 佛山推启农业研究院(普通合伙) | A kind of lactagogue forage and preparation method thereof |
| CN112870215A (en) * | 2018-09-26 | 2021-06-01 | 甘肃中医药大学 | Application of angelica polysaccharide |
| CN110283257A (en) * | 2019-06-28 | 2019-09-27 | 浙江理工大学 | A kind of extracting method of Radix Angelicae Sinensis polysaccharide |
| CN111297888A (en) * | 2020-04-01 | 2020-06-19 | 中国人民解放军第四军医大学 | Application of angelica polysaccharide in colitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1273493C (en) | 2006-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1704085A (en) | Pharmaceutical composition with immunoregulation function and method for preparing the same | |
| CN1273493C (en) | Angelica polysaccharide and its preparation and use | |
| CN1899491A (en) | Method for preparing paris polyphylla total saponin and its use | |
| CN1287490A (en) | Pharmaceutical composition having antitumor activity and process for the preparation thereof | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN1522746A (en) | Rhodiola root medicinal preparation and preparation method and application thereof | |
| CN1272026C (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1857678A (en) | Mastoproliferation treating medicine and its preparing method | |
| CN1301544A (en) | Medicinal composition for curing arthritis and osteoarthropathy and its preparing method | |
| CN1927293A (en) | Chinese medicine composition for treating skin burn and scald | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1775229A (en) | Chinese medicine dropping pill for promoting blood circulation, removing blood stasis, alleviating pain and detumescence and its preparing method | |
| CN1931190A (en) | Toad skin extract and its medicine prepn and their prepn | |
| CN118286310B (en) | Application of Rhizoma Cynomorii or its extract and composition in treating and/or preventing liver damage | |
| CN1438027A (en) | Chinese medicine for treating breast disease | |
| CN1718232A (en) | A compound preparation for treating acute gastrointestinal inflammation and anti-influenza virus and its preparation method | |
| CN1698803A (en) | Compound notoginseng injection and its preparation process | |
| CN1853689A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and making method thereof | |
| CN1237989C (en) | Drug for upper respiratory tract infection | |
| CN1634212A (en) | Production method and product of hepatitis therapeutic drug | |
| CN115887590A (en) | Mongolian medicine medicated bath composition for treating psoriasis as well as preparation method and application thereof | |
| CN1931208A (en) | Application of common goldenrod herb in preparing medicine for preventing and treating H5N1 bird flu and influenza | |
| CN1823884A (en) | Preparation method of aidi injection agent | |
| CN1634246A (en) | Compound formulation of breviscapine and asarum herb for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN112316062A (en) | Traditional Chinese medicine composition for treating migraine, nasal gel, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |